Your browser is no longer supported. Please, upgrade your browser.
Settings
DEPO DepoMed Inc. daily Stock Chart
DEPO [NASD]
DepoMed Inc.
Index- P/E15.45 EPS (ttm)1.35 Insider Own0.40% Shs Outstand59.96M Perf Week-5.61%
Market Cap1.25B Forward P/E17.41 EPS next Y1.20 Insider Trans-2.04% Shs Float59.30M Perf Month-3.29%
Income102.20M PEG0.52 EPS next Q-0.03 Inst Own77.30% Short Float23.65% Perf Quarter-7.62%
Sales346.00M P/S3.61 EPS this Y173.30% Inst Trans22.08% Short Ratio9.01 Perf Half Y32.19%
Book/sh6.05 P/B3.45 EPS next Y317.42% ROA18.40% Target Price27.43 Perf Year45.87%
Cash/sh1.02 P/C20.47 EPS next 5Y30.00% ROE41.20% 52W Range9.85 - 28.16 Perf YTD29.48%
Dividend- P/FCF186.68 EPS past 5Y46.60% ROI25.60% 52W High-25.92% Beta1.02
Dividend %- Quick Ratio9.80 Sales past 5Y46.60% Gross Margin95.80% 52W Low111.78% ATR0.82
Employees324 Current Ratio9.90 Sales Q/Q-57.90% Oper. Margin55.30% RSI (14)43.11 Volatility4.54% 3.69%
OptionableYes Debt/Eq0.68 EPS Q/Q-166.70% Profit Margin34.70% Rel Volume1.05 Prev Close21.46
ShortableYes LT Debt/Eq0.68 EarningsAug 06 AMC Payout0.00% Avg Volume1.56M Price20.86
Recom2.10 SMA20-3.73% SMA50-6.64% SMA2008.54% Volume1,640,064 Change-2.80%
Jun-11-15Initiated Morgan Stanley Equal-Weight $23
May-12-15Reiterated RBC Capital Mkts Outperform $29 → $26
Apr-22-15Initiated Piper Jaffray Overweight $37
Apr-06-15Reiterated ROTH Capital Buy $27 → $30
Mar-13-15Downgrade WallachBeth Buy → Hold $28 → $26
Jan-16-15Upgrade ROTH Capital Neutral → Buy $25
Jan-16-15Reiterated RBC Capital Mkts Outperform $20 → $22
Dec-10-14Initiated RBC Capital Mkts Outperform $20
Jul-10-14Initiated WallachBeth Buy $17
Feb-25-13Downgrade WallachBeth Buy → Hold $8 → $7
Jan-05-12Initiated JMP Securities Mkt Outperform $8
Sep-30-11Initiated Auriga Buy $10
Feb-18-10Downgrade Merriman Buy → Neutral
Oct-21-09Initiated Caris & Company Buy $9
Oct-12-09Reiterated Merriman Buy $11.50 → $7.50
Oct-05-09Initiated Merriman Buy
Jun-20-08Initiated Roth Capital Buy $5
Mar-15-07Reiterated Thomas Weisel Overweight $8 → $6.50
Jun-26-15 08:03AM  Why This Small Cap Biotech Stock Is Becoming One of My Favorites at Motley Fool
Jun-17-15 04:05PM  Depomed Announces Change To Presentation Time At JMP Life Sciences Conference PR Newswire
Jun-11-15 06:45AM  Coverage initiated on DepoMed by Morgan Stanley
Jun-10-15 06:02AM  DEPOMED INC Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibi
Jun-03-15 08:00AM  Depomed Announces Zipsor® ANDA Litigation Settlement Providing for Exclusivity to March 2022 PR Newswire
Jun-01-15 04:29PM  O'Malley jabs Wall Street, presidential dynasties
May-29-15 11:20AM  Who's The Next Big Pharma Acquisition?
May-26-15 04:01PM  Depomed To Present At Healthcare Conferences In June PR Newswire
May-22-15 01:04PM  DEPOMED INC Financials
May-19-15 06:01AM  DEPOMED INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements
May-16-15 12:01AM  Best 100 Hedge Funds at Barrons.com
May-13-15 08:11PM  10-Q for Depomed, Inc. at Company Spotlight
04:14PM  DEPOMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
04:01PM  Depomed To Present At Healthcare Conferences In May PR Newswire
03:27PM  Biotech provides a major plus for the stock market at MarketWatch
10:30AM  DEPO: Selloff Creates Great Opportunity In Depomed
May-12-15 03:58PM  Why the DepoMed Drop Is a Gross Overreaction at 24/7 Wall St. -16.30%
10:30AM  Depomed (DEPO) Stock Falls on Earnings Miss at TheStreet
May-11-15 08:41PM  5 Drug Stocks Moving On Earnings, Trial Data Late at Investor's Business Daily
08:27PM  Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers
05:25PM  After-hours buzz: Rackspace, Gap, Depomed & more at CNBC
04:43PM  Depomed reports 1Q loss
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:07PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Depomed Reports First Quarter 2015 Financial Results PR Newswire
07:07AM  Q1 2015 Depomed Inc Earnings Release - After Market Close
Apr-30-15 08:16AM  Depomed to Report First Quarter Fiscal Year 2015 Financial Results on Monday, May 11, 2015 at noodls -7.07%
08:00AM  Depomed to Report First Quarter Fiscal Year 2015 Financial Results on Monday, May 11, 2015 PR Newswire
Apr-23-15 04:16PM  DepoMed Set To Grow On 'Transformative' Nucynta Deal at Investor's Business Daily
Apr-22-15 02:33PM  Street Talk: DEPO under the radar
Apr-13-15 08:07AM  Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal at noodls
08:00AM  Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal PR Newswire
Apr-09-15 04:07PM  Conditions are ripe for the intermediate-term speculator at MarketWatch
Apr-02-15 04:19PM  Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion at noodls
04:12PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition
04:05PM  Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion PR Newswire
Mar-17-15 08:32AM  Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen Pharmaceuticals PR Newswire
Mar-12-15 04:42PM  Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition at noodls
04:19PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement
04:05PM  Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition PR Newswire
Mar-03-15 08:00AM  Depomed To Present At 27th Annual Roth Conference PR Newswire
Feb-28-15 07:08PM  10-K for Depomed, Inc. at Company Spotlight
Feb-26-15 06:12PM  DEPOMED INC Files SEC form 10-K, Annual Report
Feb-25-15 04:01PM  6 stocks to watch at MarketWatch
10:12AM  Depomed Reports Fourth Quarter and Full Year 2014 Financial Results at noodls
Feb-24-15 03:18PM  The Nasdaq is doing the most bullish thing a market can do at MarketWatch +10.78%
12:30PM  Depomed: The Next Big Specialty Pharma Success Story
10:36AM  Stocks Mixed As Yellen Speaks; Depomed, Home Depot, BHP Surge at Investor's Business Daily
Feb-23-15 04:31PM  Depomed tops 4Q revenue forecasts AP
04:30PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:01PM  Depomed Reports Fourth Quarter and Full Year 2014 Financial Results PR Newswire
07:07AM  Q4 2014 Depomed Inc Earnings Release - After Market Close CCBN
Feb-19-15 03:40PM  Two young stocks poised for a growth spurt at MarketWatch
Feb-12-15 08:00AM  Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015 PR Newswire
Feb-09-15 08:00AM  New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies Based on Strength of Evidence PR Newswire
Feb-06-15 05:17PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendment or Waiver to Code of Ethics EDGAR Online
Feb-04-15 08:00AM  Depomed To Present At Healthcare Conferences In February PR Newswire
Jan-20-15 09:00AM  East Bay's Depomed snags J&J pain-fighting drug in $1 billion deal at American City Business Journals -6.73%
Jan-16-15 04:34PM  U.S. markets break 5-day losing streak Yahoo Finance Contributors +14.45%
02:04PM  Mid-Day Market Update: U.S. Stocks Rise; SunTrust Shares Surge On Upbeat Earnings Benzinga
11:32AM  Depomed Hits High On Big Pain-Drug Deal With J&J at Investor's Business Daily
08:58AM  Depomed Surges 8% Following NUCYNTA Acquisition From Janssen Pharmaceuticals Benzinga
Jan-15-15 05:29PM  After-hours buzz: Intel, Regal, Depomed & more at CNBC
05:23PM  Depomed To Acquire Rights To NUCYNTA Franchise For $1.05 Billion Benzinga
05:21PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State EDGAR Online
05:00PM  Depomed Inc to Acquire the U.S. Rights to the NUCYNTA Franchise Call scheduled for 5:00 pm ET today CCBN
04:48PM  DepoMed to buy U.S. rights to Nucynta from J&J unit at MarketWatch
04:31PM  DepoMed to Buy U.S. Rights to Nucynta From J&J Unit at The Wall Street Journal
04:15PM  Depomed to pay $1 bln for J&J pain drug franchise Reuters
04:04PM  J&Js Pain Drug Is Depomeds Gain in $1.05 Billion Deal at Bloomberg
04:04PM  Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion PR Newswire
Nov-20-14 04:05PM  Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference PR Newswire
Nov-12-14 08:00AM  Depomed To Present At Stifel 2014 Healthcare Conference PR Newswire
Nov-08-14 07:07PM  10-Q for Depomed, Inc. Company Spotlight
Nov-06-14 04:28PM  DEPOMED INC Files SEC form 10-Q, Quarterly Report EDGAR Online
10:05AM  Another Solid Quarter For Depomed Zacks Small Cap Research
Nov-05-14 05:42PM  Depomed beats Street 3Q forecasts AP
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:11PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Depomed Reports Third Quarter 2014 Financial Results PR Newswire
07:07AM  Q3 2014 Depomed Inc Earnings Release - After Market Close CCBN
Oct-27-14 04:01PM  Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014 PR Newswire
Oct-07-14 12:08PM  5 places to play momentum at MarketWatch
Oct-03-14 12:00AM  OxyContin, Cialis Makers Dodge Court to Beat Patent Suits at Bloomberg
Oct-01-14 11:14AM  [video] Dan Tana's: Hollywood's Iconic Red-Sauce Joint at MarketWatch
Sep-30-14 02:54PM  Accelerated selling means its time to move to cash at MarketWatch
Sep-17-14 04:07PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
Sep-09-14 04:05PM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex EDGAR Online
Sep-05-14 05:00PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
02:34PM  Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for Gralise® (Gabapentin) PR Newswire
Sep-04-14 07:38AM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:00AM  Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021 PR Newswire
Sep-02-14 04:18PM  DEPOMED INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
04:00PM  Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 PR Newswire
Aug-25-14 04:01PM  Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference PR Newswire
Aug-21-14 04:02PM  DEPOMED INC Files SEC form 8-K, Other Events EDGAR Online
Aug-19-14 04:35PM  Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs Benzinga +13.53%
04:03PM  Nasdaq stocks posting largest percentage increases AP
11:32AM  Why DepoMed (DEPO) Stock Is Gaining Today at TheStreet
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vargas Thadd MSenior VP, BDJun 12Sale20.705,000103,500138,153Jun 15 05:16 PM
STAPLE PETER DDirectorMay 12Option Exercise6.1810,00061,80060,000May 12 09:23 PM
Schoeneck James APresident and CEOMay 12Option Exercise6.6645,679304,13461,411May 12 09:21 PM
Vargas Thadd MSenior VP, BDApr 08Option Exercise6.1854,710338,010143,153Apr 09 04:50 PM
Vargas Thadd MSenior VP, BDJan 20Option Exercise5.0319,00095,57088,443Jan 22 06:28 PM
Schoeneck James APresident and CEODec 19Option Exercise8.3640,700340,25256,432Dec 22 09:14 AM
Gosling Matthew MSenior VP, General CounselDec 02Sale15.858,819139,80832,501Dec 03 05:36 PM
Schoeneck James APresident and CEODec 02Sale15.8536,727582,23352,930Dec 03 05:35 PM
Vargas Thadd MSenior VP, BDDec 02Sale15.858,247130,74069,443Dec 03 05:35 PM
Moretti August JChief Financial OfficerDec 02Sale15.855,33984,63922,564Dec 03 05:35 PM
STAPLE PETER DDirectorNov 25Option Exercise5.0410,00050,40050,000Nov 26 04:38 PM
Gosling Matthew MSenior VP, General CounselNov 19Option Exercise6.1771,000438,07088,211Nov 21 08:00 PM
Gosling Matthew MSenior VP, General CounselNov 19Sale15.3671,0001,090,34717,211Nov 21 08:00 PM
Schoeneck James APresident and CEOAug 01Option Exercise6.1130,000183,30042,898Aug 04 10:46 AM